From this initial cohort, we excluded patient samples without RNAseq data as well as patient samples with TP53 mutations classified as benign, likely benign, or uncertain significance/conflicting interpretations, for a final dataset of 492 samples from 489 patients (3 cases of bilateral tumours. The gene discussed is TP53; the disease is neoplasm.